Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells

Background Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of survival molecules. We hypothesised that dormant cancer cells, already low in RNA, might be sensitive to apoptosis induced by RNA Polymerase II (R...

Full description

Bibliographic Details
Main Authors: Pallis, Monica, Burrows, Francis, Whittall, Abigail, Boddy, Nicholas, Seedhouse, Claire, Russell, Nigel
Format: Article
Published: BioMed Central 2013
Subjects:
Online Access:https://eprints.nottingham.ac.uk/2459/
_version_ 1848790790665404416
author Pallis, Monica
Burrows, Francis
Whittall, Abigail
Boddy, Nicholas
Seedhouse, Claire
Russell, Nigel
author_facet Pallis, Monica
Burrows, Francis
Whittall, Abigail
Boddy, Nicholas
Seedhouse, Claire
Russell, Nigel
author_sort Pallis, Monica
building Nottingham Research Data Repository
collection Online Access
description Background Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of survival molecules. We hypothesised that dormant cancer cells, already low in RNA, might be sensitive to apoptosis induced by RNA Polymerase II (RP2) inhibitors that further reduce RNA synthesis. Methods We cultured leukaemia cells continuously in vitro in the presence of an mTOR inhibitor to model dormancy. Apoptosis, damage, RNA content and reducing capacity were evaluated. We treated dormancy-enriched cells for 48 hours with the nucleoside analogues ara-C, 5-azacytidine and clofarabine, the topoisomerase targeting agents daunorubicin, etoposide and irinotecan and three multikinase inhibitors with activity against RP2 - flavopiridol, roscovitine and TG02, and we measured growth inhibition and apoptosis. We describe use of the parameter 2 × IC50 to measure residual cell targeting. RNA synthesis was measured with 5-ethynyl uridine. Drug-induced apoptosis was measured flow cytometrically in primary cells from patients with acute myeloid leukaemia using a CD34/CD71/annexinV gating strategy to identify dormant apoptotic cells. Results Culture of the KG1a cell line continuously in the presence of an mTOR inhibitor induced features of dormancy including low RNA content, low metabolism and low basal ROS formation in the absence of a DNA damage response or apoptosis. All agents were more effective against the unmanipulated than the dormancy-enriched cells, emphasising the chemoresistant nature of dormant cells. However, the percentage of cell reduction by RP2 inhibitors at 2 × IC50 was significantly greater than that of other agents. RP2 inhibitors strongly inhibited RNA synthesis compared with other drugs. We also showed that RP2 inhibitors induce apoptosis in proliferating and dormancy-enriched KG1a cells and in the CD71neg CD34pos subset of primary acute myeloid leukaemia cells. Conclusion We suggest that RP2 inhibitors may be a useful class of agent for targeting dormant leukaemia cells.
first_indexed 2025-11-14T18:18:13Z
format Article
id nottingham-2459
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:18:13Z
publishDate 2013
publisher BioMed Central
recordtype eprints
repository_type Digital Repository
spelling nottingham-24592020-05-04T16:37:22Z https://eprints.nottingham.ac.uk/2459/ Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells Pallis, Monica Burrows, Francis Whittall, Abigail Boddy, Nicholas Seedhouse, Claire Russell, Nigel Background Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of survival molecules. We hypothesised that dormant cancer cells, already low in RNA, might be sensitive to apoptosis induced by RNA Polymerase II (RP2) inhibitors that further reduce RNA synthesis. Methods We cultured leukaemia cells continuously in vitro in the presence of an mTOR inhibitor to model dormancy. Apoptosis, damage, RNA content and reducing capacity were evaluated. We treated dormancy-enriched cells for 48 hours with the nucleoside analogues ara-C, 5-azacytidine and clofarabine, the topoisomerase targeting agents daunorubicin, etoposide and irinotecan and three multikinase inhibitors with activity against RP2 - flavopiridol, roscovitine and TG02, and we measured growth inhibition and apoptosis. We describe use of the parameter 2 × IC50 to measure residual cell targeting. RNA synthesis was measured with 5-ethynyl uridine. Drug-induced apoptosis was measured flow cytometrically in primary cells from patients with acute myeloid leukaemia using a CD34/CD71/annexinV gating strategy to identify dormant apoptotic cells. Results Culture of the KG1a cell line continuously in the presence of an mTOR inhibitor induced features of dormancy including low RNA content, low metabolism and low basal ROS formation in the absence of a DNA damage response or apoptosis. All agents were more effective against the unmanipulated than the dormancy-enriched cells, emphasising the chemoresistant nature of dormant cells. However, the percentage of cell reduction by RP2 inhibitors at 2 × IC50 was significantly greater than that of other agents. RP2 inhibitors strongly inhibited RNA synthesis compared with other drugs. We also showed that RP2 inhibitors induce apoptosis in proliferating and dormancy-enriched KG1a cells and in the CD71neg CD34pos subset of primary acute myeloid leukaemia cells. Conclusion We suggest that RP2 inhibitors may be a useful class of agent for targeting dormant leukaemia cells. BioMed Central 2013-06-15 Article PeerReviewed Pallis, Monica, Burrows, Francis, Whittall, Abigail, Boddy, Nicholas, Seedhouse, Claire and Russell, Nigel (2013) Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC Pharmacology and Toxicology, 14 (June). 11/1-11/11. ISSN 2050-6511 Leukemia Dormancy RNA polymerase II inhibitors http://www.biomedcentral.com/2050-6511/14/32 doi:10.1186/2050-6511-14-32 doi:10.1186/2050-6511-14-32
spellingShingle Leukemia
Dormancy
RNA polymerase II inhibitors
Pallis, Monica
Burrows, Francis
Whittall, Abigail
Boddy, Nicholas
Seedhouse, Claire
Russell, Nigel
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
title Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
title_full Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
title_fullStr Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
title_full_unstemmed Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
title_short Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
title_sort efficacy of rna polymerase ii inhibitors in targeting dormant leukaemia cells
topic Leukemia
Dormancy
RNA polymerase II inhibitors
url https://eprints.nottingham.ac.uk/2459/
https://eprints.nottingham.ac.uk/2459/
https://eprints.nottingham.ac.uk/2459/